Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials
GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)
Disease Progression in Patients with Cystic Fibrosis Treated with Ivacaftor: Data From National US and UK Registries
Concentration of Fractional Excretion of Nitric Oxide (FENO): A Potential Airway Biomarker of Restored CFTR Function
Long-term improvement of lung clearance index in patients with mild cystic fibrosis lung disease: Does hypertonic saline play a role?
